Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab vedotin retreatment in cHL and PTCL
NCT03947255Phase 2Terminated
- Sponsor
- Seagen Inc.
- Start
- Oct 2019
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brentuximab vedotin in classic Hodgkin lymphoma (cHL), Anaplastic Large Cell Lymphoma (ALCL), peripheral T-cell lymphoma (PTCL), sponsored by Seagen Inc.. Started Oct 2019; status: terminated.
02
Drugs
brentuximab vedotin
03
Conditions
classic Hodgkin lymphoma (cHL)Anaplastic Large Cell Lymphoma (ALCL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT03947255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03947255.